Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists evaluated as part of a program focused on the development of best-in-class therapies for metabolic diseases.

Nov 4, 2024 · VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.

Feb 27, 2024 · Additionally, the study showed VK2735 treatment to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorized as mild or moderate. Based on these findings, Viking intends to meet with the FDA and discuss next steps in the development of VK2735.

Jan 8, 2025 · Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated ...

Mar 26, 2024 · Based on these Phase 1 results, the company plans to initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later this year. Highlights from the study results include: Body...

Mar 28, 2023 · Based on these Phase 1 results, the company plans to initiate a Phase 2 study of VK2735 in patients with obesity in mid-2023. In the SAD portion of the study, VK2735 demonstrated promising safety...

Jul 25, 2024 · Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.

Nov 4, 2024 · New clinical trial data regarding Viking Therapeutics' VK2735, an investigational dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, will be highlighted at ObesityWeek 2024, being held November 3-6 …

Jan 8, 2025 · Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.

Oct 23, 2023 · VK2735 is in development for the potential treatment of various metabolic disorders such as obesity. Viking expects to report data from the study in the first half of 2024.